The Beneficial Effect Of Renadyl (Kibow) Probiotics On Patients With Chronic Kidney Diseases, With Comparison Between Diabetic And Non Diabetic Patients
Renadyl probiotic dietary supplement is a safe product to be used in patients with chronic kidney disease stage three and four
with significant decrease in blood urea.
Introduction: The aims of the study are to study the effect of Kibow biotic (K.B. = Renadyl Tm) probiotic dietary
supplements in decreasing the blood urea and serum creatinine in patients with chronic kidney disease (CKD) stage 3 and 4
and to study the effect of the (K.B.) by comparison between diabetic and non-diabetic CKD patients.
Method: This was a prospective, randomized, double blind, placebo controlled, crossover study of probiotic bacteria dietary
supplement (Kibow=KB) conducted on 25 outpatients with CKD stage 3 and 4. The study divided the patients into two
groups: Group A, 11 Diabetic patients, received the probiotic bacteria in the formulation (KB). Group B, 14 non diabetic
patients received the placebo. After 3 months, cross over was made. Results: In comparison with the placebo period, blood
urea levels were significantly lower during the KB treatment for both groups. However, the serum creatinine changes were
not significant in diabetic group. There was a little effect of the KB on the serum creatinine in six of the patients, who
needed chronic antibiotic medications.
Discussion: The Renadyl probiotic dietary supplement is a safe product to be used our patients with CKD stage 3 and 4
withsignificant decrease in blood urea in all the patients. There was no significant change in serum creatinine in diabetic
patient because of low effect of the KB product on patients using antibiotic for long time, because of the presence of
neurogenic bladder in some of them. We recommend to do a studies on larger group of patients, for longer periodand
exclude diabetic patients with neurogenic bladder from the studies.
Key messages- Beneficial effect of probiotics, chronic kidney disease